American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share
- Symbol
- IMCR
- Exchange
- NASDAQ
- Classification
- ADS
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Immunocore Holdings plc
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 6, 2026, Immunocore Holdings plc (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.…
Press release in this filing
Immunocore reports second quarter financial results and provides a business update →Company context
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Current securities
Registered securities in this filing
Immunocore Holdings plc · 8-K · Filed 2026-08-06
Ordinary share, nominal value £0.002 per share*
- Symbol
- No trading symbol declared
- Exchange
- NASDAQ
- Classification
- COMMON
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On August 6, 2026, Immunocore Holdings plc (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2026, as well as other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
The information in this Item 2.02 of this Current Report on 8-K, including Exhibits 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.